Sentence examples for her pathways from inspiring English sources

We also observed the recovery of phospho-PKB (Ser473) and phospho-ERK1/2 within 48 hours (Figure 3B, lower panels), consistent with activation of alternative HER pathways including HER2/HER3 and HER2/HER4 via autocrine release of ligands.

Dual targeting of mTOR and upstream HER pathways, along with endocrine therapy, is likely to be more effective.

The crosstalk between the oestrogen receptor pathway and growth factor pathways, such as the HER pathways, is a prime example of ongoing research.

In addition, the IGF pathway as well as other human epidermal growth factor receptor (HER) pathways are present and thought to be active in ovarian cancer (Hamburger, 2001; Mayr et al., 2006).

Several drugs have been developed and are in clinical use to block the HER pathway, most aimed at the receptor level.

The increased protein levels of ER and PR observed in BT474 LR cells decreased in BT474 LLR, as the HER pathway became active once more.

The incorporation of markers such as HER3 transactivation, HER2/HER3 dimer, or others that may provide information regarding the level of HER pathway engagement has been demonstrated to allow identification of patients who respond to or escape HER-targeted therapies.

Generally, the overall HER pathway, simply written as 2H+ + 2e– → H2, can be described by a three-state diagram comprising of an initial state H+ + e–, an intermediate adsorbed H*, and the final product /2H2.

In this report we show that a dynamic transition between HER2 and ER activity plays a role in resistance to L-containing regimens, while sustained HER pathway activity is a prominent feature in TR cells.

Together with the results of the HER receptor quantitation, these findings indicate that ER activity provides a survival stimulus for LR BT474 cells in the early phase of their acquired resistance; however, with more prolonged L treatment, levels of HER2, HER3, and multiple HER ligands increase, and the HER pathway once again becomes the dominant driver of proliferation and survival.

However, incorporation of markers such as HER3 transactivation, HER2/HER3 dimer, or others that may provide information regarding the level of HER pathway engagement and so allow identification of patients who respond to or escape HER-targeted therapies has already been proposed [ 12, 13].